CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-κB activation

  1. Brian C. Grabiner1,5,
  2. Marzenna Blonska1,5,
  3. Pei-Chun Lin1,
  4. Yun You1,
  5. Donghai Wang4,
  6. Jiyuan Sun1,
  7. Bryant G. Darnay2,
  8. Chen Dong3, and
  9. Xin Lin1,6
  1. 1 Department of Molecular and Cellular Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA;
  2. 2 Department of Experimental Therapeutics, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA;
  3. 3 Department of Immunology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA;
  4. 4 The CBR Institute for Biomedical Research, Harvard Medical School, Boston, Massachusetts 02115, USA
  1. 5 These authors contributed equally to this work.

Abstract

G protein-coupled receptors (GPCRs) play pivotal roles in regulating various cellular functions. Although many GPCRs induce NF-κB activation, the molecular mechanism of GPCR-induced NF-κB activation remains largely unknown. CARMA3 (CARD and MAGUK domain-containing protein 3) is a scaffold molecule with unknown biological functions. By generating CARMA3 knockout mice using the gene targeting approach, here we show CARMA3 is required for GPCR-induced NF-κB activation. Mechanistically, we found that CARMA3 deficiency impairs GPCR-induced IκB kinase (IKK) activation, although it does not affect GPCR-induced IKKα/β phosphorylation, indicating that inducible phosphorylation of IKKα/β alone is not sufficient to induce its kinase activity. We also found that CARMA3 is physically associated with NEMO/IKKγ, and induces polyubiquitination of an unknown protein(s) that associates with NEMO, likely by linking NEMO to TRAF6. Consistently, we found TRAF6 deficiency also abrogates GPCR-induced NF-κB activation. Together, our results provide the genetic evidence that CARMA3 is required for GPCR-induced NF-κB activation.

Keywords

Footnotes

| Table of Contents

Life Science Alliance